Neumora Therapeutics IPO Presentation Deck

Navacaprant: MDD Market in U.S. Provides Potential Large Blockbuster Opportunity for Differentiated Product with Novel Mechanism of Action MDD Market Represents Large Patient Opportunity 21M Patients Diagnosed in U.S. 50% not on therapy 11M Patients Pharmacologically Treated 1st line 47% 5.2M patients 2nd line 26% 2.8M patients Upside drivers 3rd line 16% 1.8M patients 4th line 11% Navacaprant adjustments: Adoption, Competition, Market Access, Compliance 3-5% Net Penetration (330-550K patients treated) Safer agent drives treatment seeking 1.2M patients Patients fast fail 1st line Neuropsychology Pricing Catalogues GTN discount Rexulti Vraylar Nuplazid Auvelity WAC (per month) $1,419 $1,378 Safer agent drives compliance $4,565 $1,080 -36% Pharmacy Director, Anthem BCBS OH -32% -20% "...is a combo of two products that exist; I would expect a pretty steep discount, for example 50-60% is going to be what it takes ... [navacaprant] is a lower discount since it is a unique MOA...' Executive, Magellan -50% "... 15-25% or up to 30% are reasonable discounts [for navacaprant] a few years after launch, given it's a new MoA as an antidepressant, that's a big benefit..." Inflation adjusted pricing Confidential 15

View entire presentation